Oxaliplatin. Market analysis

Nature Reviews Drug Discovery

Volumn 3, Issue 1, 2004, Pages 11-12

  Graham, Joanne ^b   Muhsin, Mohamed ^b   Kirkpatrick, Peter ^a  

^a Nature Reviews Drug Discovery ^*

^b Decision Resources Intl   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; VASCULOTROPIN; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CROSS RESISTANCE; DRUG APPROVAL; DRUG CONFORMATION; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UNITED STATES; ARTICLE; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; ECONOMICS; FINANCIAL MANAGEMENT; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MARKETING OF HEALTH SERVICES; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS;

EID: 0346505345     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1287     Document Type: Note

References (9)

1. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-S66 (2001).
2. Longley, D. B. et al. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3, 330-338 (2003).
3. Jamieson, E. R. & Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498 (1999).
4. Di Francesco, A. M. et al. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell. Mol. Life Sci. 59, 1914-1927 (2002).
5. Raymond, E. et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25, 4-12 (1998).
6. Rixe, O, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol. 52, 1855-1865 (1996).
7. FDA Drug Approvals List [online], (cited 28 November 2003), (2002).
8. Goldberg, R. M. et al. A randomized controlled trial of flourouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. Dec 9 2003 (doi: 10.1200/JCO.2004.09.046)
9. De Gramont, A. et al. Oxaloplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc. Am. Soc. Clin. Oncol. 22, 253 (2003).